Oppenheimer Upgrades Marinus Pharma to Outperform, Announces $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has upgraded Marinus Pharma (NASDAQ:MRNS) from Perform to Outperform, setting a price target of $6.
September 23, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has upgraded Marinus Pharma to Outperform with a $6 price target, indicating a positive outlook for the stock.
The upgrade from Perform to Outperform by a reputable analyst like Jay Olson at Oppenheimer suggests increased confidence in Marinus Pharma's future performance. The $6 price target indicates potential upside, likely leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100